The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries
暂无分享,去创建一个
David Goldblatt | W. John Edmunds | Elizabeth Miller | Stefan Flasche | K. O'Brien | W. Edmunds | J. Scott | D. Goldblatt | S. Flasche | E. Miller | A. V. van Hoek | J. Anthony G. Scott | Katherine L. O’Brien | Albert Jan Van Hoek | A. Hoek | J. Scott
[1] G. Garnett,et al. ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES , 2006 .
[2] M. Lipsitch,et al. Pneumococcal Carriage and Antibiotic Resistance in Young Children Before 13-valent Conjugate Vaccine , 2012, The Pediatric infectious disease journal.
[3] K. O'Brien,et al. Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Nasopharyngeal Carriage , 2013, The Pediatric infectious disease journal.
[4] David Goldblatt,et al. Immunogenicity of, and Immunologic Memory to, a Reduced Primary Schedule of Meningococcal C-Tetanus Toxoid Conjugate Vaccine in Infants in the United Kingdom , 2003, Infection and Immunity.
[5] Dallas,et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[6] N. Andrews,et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. , 2014, The Lancet. Infectious diseases.
[7] K. O'Brien,et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] N. Andrews,et al. Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom , 2010, The Pediatric infectious disease journal.
[9] N. Andrews,et al. Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers , 2006, The Pediatric infectious disease journal.
[10] T. Cherian,et al. Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites , 2013, PLoS medicine.
[11] W. Edmunds,et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis , 2012, BMJ : British Medical Journal.
[12] D. Greenberg,et al. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. , 2012, Vaccine.
[13] S. Madhi,et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. , 2003, The New England journal of medicine.